"If" is no longer a legitimate question about PPHM share price rise, but "when". My annual (& perpetual) prediction:
PPHM share price goes up "when" big money interests are aligned. Our job is to be certain as stockholders we get our fair share, poof-positive that "altruistic investments" and IHUB communications pay off. Keep up the good work here folks. But more science now maybe?
"Free The Mice(!)...reincarnate or reappear. Please? Your fan-base is pleading. Another infusion of exciting,fresh, theoretical scientific optimism. The board's conjecture about trial is interesting, but a bit overwrought IMO, and a distraction from what is many times more important.
The PPHM anti-PS platform...not simply Bavituximab marketed by PPHM for incurable lung cancer... but THE entire anti-phospholipid platform is PPHM,s and well might define the idea of a "disruptive technology".
Bavituximab is only the flagship for this platform, one that exploits a unique docking site on a single cell...and not any cell, but those cells with cancer, or those affected by cancer, such as endothelial cell nourishing the cancer. But there are other inflammatory disease targets in the future. The myriad possibilities of Bavi-like drugs is intriguing, but also a diversion. Today we are focused on Bavi approval. Phase III in FDA pipeline. Patient enrollment good. Bavituximab, as a first example of PPHM technology, has passed through the most harrowing of FDA pipeline journeys, with exhaustive animal trials, and now human trials, one of which apparently sabotaged. Bavituximab is unquestionably safe. Side effect profile is apparently very good. It has significant accumulation at tumor, e.g. great "site specificity". Bavi- is an immunological adjunct. It excites the body immunocyte killers. Bavi-like fully humanized monoclonal antibodies can carry a payload to tumor. Bavituximab is an established double-tasker. A Bavi-byproduct carries x-ray dyes to tumor while it also encourages immunocytes to attack the tumor. Imagine following tumor progression or treatment response with Bavituximab. Naked Bavi-, or Bavi- used alone, is apparently weakly cytotoxic to cancers of several types, and occupies a unique and important niche in the immunologic attack on cancer. Bavi- is not a cure. It is a safe stone on the way across a rocky stream where on the other side is cancer not as a killer, but as a chronic disease. Obviously if Bavi is used early it will have greater application than for large, bulky, metastasized, incurable tumor. Bavi used early and frequenly appears to be where this can go. Bavi has, if memory serves, great penetration of the nasal mucosa. Better than Flonase. Bavi- is a no brainer. Warning: I thought the same of Erbitux and Cotara. What are we waiting for? The money guys to get it together. Let's move the ball closer to the goal. Cheers!
